company background image
SAME

Sarana Meditama Metropolitan IDX:SAME Stock Report

Last Price

Rp350.00

Market Cap

Rp6.0t

7D

-14.2%

1Y

-33.3%

Updated

16 May, 2022

Data

Company Financials
SAME fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

SAME Stock Overview

PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta.

Sarana Meditama Metropolitan Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sarana Meditama Metropolitan
Historical stock prices
Current Share PriceRp350.00
52 Week HighRp815.00
52 Week LowRp306.00
Beta0.80
1 Month Change-16.67%
3 Month Change2.94%
1 Year Change-33.33%
3 Year Change-33.33%
5 Year Change-37.72%
Change since IPO284.62%

Recent News & Updates

Shareholder Returns

SAMEID HealthcareID Market
7D-14.2%0.05%-3.6%
1Y-33.3%12.3%14.9%

Return vs Industry: SAME underperformed the ID Healthcare industry which returned 12.1% over the past year.

Return vs Market: SAME underperformed the ID Market which returned 12.6% over the past year.

Price Volatility

Is SAME's price volatile compared to industry and market?
SAME volatility
SAME Average Weekly Movement7.7%
Healthcare Industry Average Movement5.1%
Market Average Movement6.2%
10% most volatile stocks in ID Market11.9%
10% least volatile stocks in ID Market3.0%

Stable Share Price: SAME is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: SAME's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19842,370Jusup Halimihttps://www.emc.id

PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta. The company was founded in 1984 and is based in Jakarta, Indonesia. PT Sarana Meditama Metropolitan Tbk is a subsidiary of PT Elang Mahkota Teknologi Tbk.

Sarana Meditama Metropolitan Fundamentals Summary

How do Sarana Meditama Metropolitan's earnings and revenue compare to its market cap?
SAME fundamental statistics
Market CapRp6.00t
Earnings (TTM)Rp116.47b
Revenue (TTM)Rp1.29t

51.5x

P/E Ratio

4.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAME income statement (TTM)
RevenueRp1.29t
Cost of RevenueRp805.11b
Gross ProfitRp486.94b
Other ExpensesRp370.47b
EarningsRp116.47b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)6.80
Gross Margin37.69%
Net Profit Margin9.01%
Debt/Equity Ratio2.6%

How did SAME perform over the long term?

See historical performance and comparison

Valuation

Is Sarana Meditama Metropolitan undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


51.48x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SAME's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SAME's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: SAME is poor value based on its PE Ratio (51.5x) compared to the ID Healthcare industry average (19.8x).

PE vs Market: SAME is poor value based on its PE Ratio (51.5x) compared to the ID market (18.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SAME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SAME is good value based on its PB Ratio (1.6x) compared to the ID Healthcare industry average (1.9x).


Future Growth

How is Sarana Meditama Metropolitan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sarana Meditama Metropolitan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Sarana Meditama Metropolitan performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-10.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SAME has high quality earnings.

Growing Profit Margin: SAME became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: SAME's earnings have declined by 10.2% per year over the past 5 years.

Accelerating Growth: SAME has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SAME has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (121.6%).


Return on Equity

High ROE: SAME's Return on Equity (2.7%) is considered low.


Financial Health

How is Sarana Meditama Metropolitan's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SAME's short term assets (IDR700.9B) exceed its short term liabilities (IDR303.0B).

Long Term Liabilities: SAME's short term assets (IDR700.9B) exceed its long term liabilities (IDR263.4B).


Debt to Equity History and Analysis

Debt Level: SAME has more cash than its total debt.

Reducing Debt: SAME's debt to equity ratio has reduced from 52.4% to 2.6% over the past 5 years.

Debt Coverage: SAME's debt is well covered by operating cash flow (221.3%).

Interest Coverage: SAME's interest payments on its debt are well covered by EBIT (28.6x coverage).


Balance Sheet


Dividend

What is Sarana Meditama Metropolitan current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SAME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SAME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SAME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SAME's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: SAME is not paying a notable dividend for the ID market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SAME has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Jusup Halimi

2.33yrs

Tenure

Mr. Jusup Halimi serves as President Director and Chief Executive Officer of PT Sarana Meditama Metropolitan Tbk since 2020. He served as a Manager of Indonesian Operations of Affinity Health Ltd., and was...


Board Members

Experienced Board: SAME's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44%.


Top Shareholders

Company Information

PT Sarana Meditama Metropolitan Tbk's employee growth, exchange listings and data sources


Key Information

  • Name: PT Sarana Meditama Metropolitan Tbk
  • Ticker: SAME
  • Exchange: IDX
  • Founded: 1984
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Implied Market Cap: Rp5.995t
  • Shares outstanding: 17.13b
  • Website: https://www.emc.id

Number of Employees


Location

  • PT Sarana Meditama Metropolitan Tbk
  • Jalan Pulomas Barat VI No. 20
  • Kayu Putih
  • Jakarta
  • Jakarta Raya
  • 13210
  • Indonesia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.